3M Biotech Co., Ltd

Based on technology,Create the future.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAnti Estrogen Steroids

CAS 82640-04-8 Raloxifene Hydrochloride , Raloxifene HCL For Breast Cancer

CAS 82640-04-8 Raloxifene Hydrochloride , Raloxifene HCL For Breast Cancer

CAS 82640-04-8 Raloxifene Hydrochloride , Raloxifene HCL For Breast Cancer

Product Details:

Place of Origin: China
Brand Name: Rund
Certification: ISO9001
Model Number: CAS 82640-04-8

Payment & Shipping Terms:

Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: 10/100/250/500/1000g/foil bag
Delivery Time: 2-3 days
Payment Terms: T/T, Western Union, MoneyGram, BTCcoin
Supply Ability: 1000kg per momth
Contact Now
Detailed Product Description
Product Name: Raloxifene Hydrochloride CAS: 82640-04-8
Appearance: Light Yellow Powder MF: C28H28ClNO4S
MW: 510.04 Assay: 99%

Breast Cancer Osteoporosis Raw Steroid Powders CAS 82640-04-8 Raloxifene hydrochloride/Raloxifene HCL
 
Details

 

Product name:Raloxifene hydrochloride

Alias: Raloxifene HCL;KEOXIFENE;AKOS 92138

CAS Registry Number:82640-04-8

Purity: 99%

MF: C28H28ClNO4S

MW: 510.04

Appearance:light yellow powder

Related Substances : Pharmaceutical Grade

Storage: Shading, confined preservation

Usage :It is used in the prevention of osteoporosis in postmenopausal women.

 

 

Description

 

Product name Raloxifene hydrochloride
Other name Raloxifene HCL;KEOXIFENE;AKOS 92138
CAS register number 82640-04-8
Molecular formula C28H28ClNO4S
Molecular weight 510.04
Molecular structure Healthy Anti Estrogen Steroids Raloxifene Hydrochloride Raloxifene For Breast Cancer Treatment
Melting point 250-253°C
Assay 99%

 

Application

 

May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

 

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

 

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

 

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer.1 Not indicated for reduction in the risk of noninvasive breast cancer.

 

Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i.e., can cause developmental abnormalities such as birth defects.

 

Specification

 

ITEMS SPECIFICATION RESULT
Appearance Light Yellow Powder Conform

 

Solubility

Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water

 

Conform

Identifications Infrared Absorption Conform
  Chloride Conform

Tests

 

Loss on drying ≤0.5% 0.4%
  Residue on ignition ≤0.1% 0.06%
  Heavy metals ≤10ppm Conform

 

RRelated substances

 

Raloxifene Impurity1 ≤0.20 % 0.10%
 

Any unspecified individual impurity 2

 

≤0.10% Max. 0.08%
  Total impurities ≤0.50% 0.40%
Assay Raloxifene HCl ≥98.0% 99.0%

Contact Details
3M Biotech Co., Ltd

Contact Person: Mr. Dr. Zhang

Send your inquiry directly to us (0 / 3000)